Cargando…

Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma

BACKGROUND: Neuroblastoma is a childhood cancer derived from immature cells of the sympathetic nervous system. The disease is clinically heterogeneous, ranging from neuronal differentiated benign ganglioneuromas to aggressive metastatic tumours with poor prognosis. Amplification of the MYCN oncogene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henriksen, Jørn R, Haug, Bjørn Helge, Buechner, Jochen, Tømte, Ellen, Løkke, Cecilie, Flaegstad, Trond, Einvik, Christer
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Methodology Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022612/ https://www.ncbi.nlm.nih.gov/pubmed/21194500 http://dx.doi.org/10.1186/1471-213X-11-1

Ejemplares similares

Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma
por: Buechner, J, et al.
Publicado: (2011)

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
por: Hald, Øyvind H., et al.
Publicado: (2018)

MicroRNA-193b-3p represses neuroblastoma cell growth via downregulation of Cyclin D1, MCL-1 and MYCN
por: Roth, Sarah Andrea, et al.
Publicado: (2018)

Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma
por: Utnes, Peter, et al.
Publicado: (2019)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

Hsa-miR-323a-3p functions as a tumor suppressor and targets STAT3 in neuroblastoma cells
por: Bhavsar, Swapnil Parashram, et al.
Publicado: (2023)

Targeting condensin, a vital spot of MYCN-amplified neuroblastoma
por: Tanno, Yuji, et al.
Publicado: (2014)

Multi-omic profiling of MYCN-amplified neuroblastoma cell-lines
por: Dassi, Erik, et al.
Publicado: (2015)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

Comparison of RNAi efficiency mediated by tetracycline-responsive H1 and U6 promoter variants in mammalian cell lines
por: Henriksen, Jørn R., et al.
Publicado: (2007)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

MYCN-amplified neuroblastoma cell-derived exosomal miR-17-5p promotes proliferation and migration of non-MYCN amplified cells
por: Chen, Weiming, et al.
Publicado: (2021)

Editorial: Molecular Mechanisms and Treatment of MYCN-Driven Tumors
por: Suenaga, Yusuke, et al.
Publicado: (2021)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016)

Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas
por: Petrov, Ivan, et al.
Publicado: (2017)

Serine–glycine-one-carbon metabolism: vulnerabilities in MYCN-amplified neuroblastoma
por: Zhao, Erhu, et al.
Publicado: (2020)

EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma
por: Durbin, Adam D., et al.
Publicado: (2022)

Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
por: Valind, Anders, et al.
Publicado: (2023)

The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma
por: Wang, Donghai, et al.
Publicado: (2023)

Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression
por: Carter, R, et al.
Publicado: (2012)

Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
por: Su, Yan, et al.
Publicado: (2020)

Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells
por: Lee, Yu-Jen, et al.
Publicado: (2019)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells
por: O’Brien, Eleanor M., et al.
Publicado: (2018)

The MYCN inhibitor BGA002 restores the retinoic acid response leading to differentiation or apoptosis by the mTOR block in MYCN-amplified neuroblastoma
por: Lampis, Silvia, et al.
Publicado: (2022)

SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2016)

Genetic variation associated with childhood and adult stature and risk of MYCN‐amplified neuroblastoma
por: Semmes, Eleanor C., et al.
Publicado: (2020)

Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma
por: Yu, Yajie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2sg8mes6o64n8olau55jkab9ok